#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea


In the context the recent Ebola outbreak, Xavier Anglaret and colleagues test an experimental treatment, favipiravir, for Ebola virus disease in a multicenter non-randomized trial.


Vyšlo v časopise: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med 13(3): e32767. doi:10.1371/journal.pmed.1001967
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001967

Souhrn

In the context the recent Ebola outbreak, Xavier Anglaret and colleagues test an experimental treatment, favipiravir, for Ebola virus disease in a multicenter non-randomized trial.


Zdroje

1. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea—preliminary report. N Engl J Med. 2014;371:1418–1425. doi: 10.1056/NEJMoa1404505 24738640

2. Kuhn J, Andersen K, Baize S, Bào Y, Bavari S, Berthet N, et al. Nomenclature- and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014. Viruses. 2014;6:4760–4799. doi: 10.3390/v6114760 25421896

3. World Health Organization. Ebola virus disease (EVD) in West Africa: an extraordinary epidemic. Wkly Epidemiol Rec. 2015;90:89–96.

4. Leroy E, Baize S, Volchkov V, Fisher-Hoch S, Georges-Courbot M, Lansoud-Soukate J, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210–2215. 10881895

5. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377:849–862. doi: 10.1016/S0140-6736(10)60667-8 21084112

6. West TE, von Saint André-von Arnim A. Clinical presentation and management of severe Ebola virus disease. Ann Am Thorac Soc. 2014;11:1341–1350. doi: 10.1513/AnnalsATS.201410-481PS 25369317

7. Schieffelin JS, Shaffer JG, Goba A, Gbakie M, Gire SK, Colubri A, et al. Clinical illness and outcomes in patients with Ebola in Sierra Leone. N Engl J Med. 2014;371:2092–2100. doi: 10.1056/NEJMoa1411680 25353969

8. Stephens DS, Ribner BS, Gartland BD, Feistritzer NR, Farley MM, Larsen CP, et al. Ebola virus disease: experience and decision making for the first patients outside of Africa. PLoS Med. 2015;12:e1001857. doi: 10.1371/journal.pmed.1001857 26218574

9. Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, et al. Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med. 2014;371:2402–2409. doi: 10.1056/NEJMoa1409838 25390460

10. Mora-Rillo M, Arsuaga M, Ramirez-Olivencia G, de la Calle F, Borobia AM, Sanchez-Seco P, et al. Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease contracted in Madrid, Spain. Lancet Respir Med. 2015;3:554–562. doi: 10.1016/S2213-2600(15)00180-0 26041403

11. World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. 2015 Jan 19 [cited 15 Sep 2015]. Available: http://www.who.int/medicines/ebola-treatment/cat_prioritization_drugs_testing/en/.

12. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104:153–155. doi: 10.1016/j.antiviral.2014.01.012 24462697

13. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–454. doi: 10.1016/j.antiviral.2013.09.015 24084488

14. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002;46:977–981. 11897578

15. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21. doi: 10.1016/j.antiviral.2014.02.014 24583123

16. MDVI. Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in Adults. ClinicalTrials.gov. 2013 Dec 8 [cited 15 Sep 2015]. Available: https://clinicaltrials.gov/ct2/show/NCT02008344.

17. Madelain V, Oestereich L, Graw F, Nguyen T, de Lamballerie X, Mentré F, et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res. 2015;123:70–77. doi: 10.1016/j.antiviral.2015.08.015 26343011

18. Mentre F, Taburet AM, Guedj J, Anglaret X, Keita S, de Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2014;15:150–151. doi: 10.1016/S1473-3099(14)71047-3 25435054

19. Bouazza N, Treluyer J-M, Foissac F, Mentré F, Taburet A-M, Guedj J, et al. Favipiravir for children with Ebola. Lancet. 2015;385:603–604.

20. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo. J Infect Dis. 1999;179:S28–S35. 9988162

21. Ksiazek T, Rollin P, Williams A, Bressler D, Martin M, Swanepoel R, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179:S177–S187. 9988182

22. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330–4341. 15047846

23. Kourtis AP, Appelgren K, Chevalier MS, McElroy A. Ebola virus disease: focus on children. Pediatr Infect Dis J. 2015;34:893–897. doi: 10.1097/INF.0000000000000707 25831417

24. Rollin PE, Bausch DG, Sanchez A. Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus. J Infect Dis2007;196:S364–S71.

25. Kortepeter MG, Bausch DG, Bray M. Basic clinical and laboratory features of filoviral hemorrhagic fever. J Infect Dis. 2011;204:S810–S816. doi: 10.1093/infdis/jir299 21987756

26. Bah EI, Lamah M-C, Fletcher T, Jacob ST, Brett-Major DM, Sall AA, et al. Clinical presentation of patients with Ebola virus disease in Conakry, Guinea. N Engl J Med. 2015;372:40–47. doi: 10.1056/NEJMoa1411249 25372658

27. ACAPS. Ebola in West Africa—Guinea: resistance to the Ebola response. ACAPS Thematic Note. 2015 Apr 24 [cited 15 Sep 2015]. Available: http://acaps.org/img/documents/t-acaps_ebola_guinea-resistance-to-ebola-response_24-april-2015.pdf.

28. Calain P, Poncin M. Reaching out to Ebola victims: coercion, persuasion or an appeal for self-sacrifice? Soc Sci Med. 2015;147:126–133. doi: 10.1016/j.socscimed.2015.10.063 26561947

29. Presidential Commission for the Study of Bioethical Issues. Ethics and Ebola: public health planning and response. 2015 Feb [cited 28 Jan 2015]. Available: http://bioethics.gov/sites/default/files/Ethics-and-Ebola_PCSBI_508.pdf.

30. Huang Y, Wei H, Wang Y, Shi Z, Raoul H, Yuan Z. Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays. Virol Sin. 2012;27:273–277. doi: 10.1007/s12250-012-3252-y 23001480

31. Tam NT, Huy NT, Thoa LTB, Long NP, Trang NTH, Hirayama K, et al. Participants understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis. Bull World Health Organ. 2015;93:186–198H. doi: 10.2471/BLT.14.141390 25883410

32. Whitehead J. The design and analysis of sequential clinical trials. 2nd ed. Chichester: John Wiley & Sons; 1997.

33. Newcombe R. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998;17:857–872. 9595616

34. Hidalgo B, Goodman M. Multivariate or multivariable regression. Am J Public Health. 2013;103:39–40. doi: 10.2105/AJPH.2012.300897 23153131

35. Copas J. Plotting p against x. Appl Stat. 1983;32:25–31.

36. Sissoko S, Folkesson E, Abdoul M, Beavogui A, Gunther S, Shepherd S, et al. Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Abstract 103-ALB. 22nd Conference on Retroviruses and Opportunistic Infections; 23–26 Feb 2015; Seattle, Washington, US. Available: http://www.croiconference.org/sessions/favipiravir-patients-ebola-virus-disease-early-results-jiki-trial-guinea.

37. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–1038.

38. Victory KR, Coronado F, Ifono SO, Soropogui T, Dahl BA, Centers for Disease Control and Prevention. Ebola transmission linked to a single traditional funeral ceremony—Kissidougou, Guinea, December, 2014–January 2015. MMWR Morb Mortal Wkly Rep. 2015;64:386–388. 25879897

39. Lanini S, Zumla A, Ioannidis JPA, Caro AD, Krishna S, Gostin L, et al. Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa? Lancet Infect Dis. 2015;15:738–745. doi: 10.1016/S1473-3099(15)70106-4 25881871

40. Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA. 2014;312:1299–1300. doi: 10.1001/jama.2014.12867 25211645

41. Chimerix. An open-label, multicenter study of the safety and anti viral activity of brincidofovir (BCV, CMX001) for Ebola virus disease. ClinicalTrials.gov. 2014 Oct 7 [cited 15 Sep 2015]. Available: https://clinicaltrials.gov/ct2/show/NCT02271347.

42. van Griensven J, Edwards T, de Lamballerie X, Semple MG, Gallian P, Baize S, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016 Jan 7;374(1):33-42. doi: 10.1056/NEJMoa1511812 26735992

43. National Institute of Allergy and Infectious Diseases. Putative investigational therapeutics in the treatment of patients with known Ebola infection. ClinicalTrials.gov. 2015 Feb 13 [cited 15 Sep 2015]. Available at: https://clinicaltrials.gov/ct2/show/NCT02363322.

44. Qiu X, Wong G, Audet J, Bello A, Fernando L, Alimonti JB, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53. doi: 10.1038/nature13777 25171469

45. Cooper BS, Boni MF, Pan-ngum W, Day NP, Horby PW, Olliaro P, et al. Evaluating clinical trial designs for investigational treatments of Ebola virus disease. PLoS Med. 2015;12:e1001815. doi: 10.1371/journal.pmed.1001815 25874579

46. Adebamowo C, Bah-Sow O, Binka F, Bruzzone R, Caplan A, Delfraissy J- F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet. 2014;384:1423–1424. doi: 10.1016/S0140-6736(14)61734-7 25390318

47. Sanchez A, Lukwiya M, Bausch D, Mahanty S, Sanchez AJ, Wagoner KD, et al. Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels. J Virol. 2004;78:10370–10377. 15367603

48. McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, et al. Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome. J Infect Dis. 2014;210:558–566. doi: 10.1093/infdis/jiu088 24526742

49. Fitzpatrick G, Vogt F, Moi Gbabai OB, Decroo T, Keane M, De Clerck H, et al. The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola case management centre, Kailahun, Sierra Leone, June–October 2014. J Infect Dis. 2015;212:1752–1758. doi: 10.1093/infdis/jiv304 26002981

50. Hunt L, Gupta-Wright A, Simms V, Tamba F, Knott V, Tamba K, et al. Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study. Lancet Infect Dis. 2015;15:1292–1299. doi: 10.1016/S1473-3099(15)00144-9 26271406

51. Schibler M, Vetter P, Cherpillod P, Petty TJ, Cordey S, Vieille G, et al. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report. Lancet Infect Dis. 2015;15:1034–1040. doi: 10.1016/S1473-3099(15)00229-7 26201298

52. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–851. doi: 10.1056/NEJMra1208623 23984731

53. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. Lancet. 2012;380:756–766. doi: 10.1016/S0140-6736(11)61454-2 22617274

54. Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21:473–494. doi: 10.1128/CMR.00001-08 18625683

55. Konrad RJ, Goodman DB, Davis WL. Tumor necrosis factor and coxsackie B4 rhabdomyolysis. Ann Intern Med. 1993;119:861.

56. Naylor C, Jevnikar A, Witt N. Sporadic viral myositis in two adults. CMAJ. 1987;137:819–821. 2832046

57. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62–72. doi: 10.1056/NEJMra0801327 19571284

58. Ramanan P, Shabman RS, Brown CS, Amarasinghe GK, Basler CF, Leung DW. Filoviral immune evasion mechanisms. Viruses. 2011;3:1634–1649. doi: 10.3390/v3091634 21994800

59. Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc Natl Acad Sci U S A. 2012;109:20661–20666. doi: 10.1073/pnas.1213559109 23185024

60. Broadhurst M, Kelly J, Miller A, Semper A, Bailey D, Groppelli E, et al. ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study. Lancet. 2015;386:867–874. doi: 10.1016/S0140-6736(15)61042-X 26119838

61. Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121:132–137. doi: 10.1016/j.antiviral.2015.07.003 26186980

62. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin. 2011;27:19–34. doi: 10.1016/j.ccc.2010.09.006 21144984

Štítky
Interné lekárstvo

Článok vyšiel v časopise

PLOS Medicine


2016 Číslo 3
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Získaná hemofilie - Povědomí o nemoci a její diagnostika
nový kurz

Eozinofilní granulomatóza s polyangiitidou
Autori: doc. MUDr. Martina Doubková, Ph.D.

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#